免疫チェックポイント阻害剤 (ICI) 治療を受けた黒色腫患者における早期 FDG PET/CT と ctDNA の相関
免疫チェックポイント阻害剤で治療された進行性黒色腫患者における初期間隔の 18F-フルオロデオキシグルコース陽電子放出断層撮影/コンピュータ断層撮影 (PET/CT) と循環腫瘍 DNA (ctDNA) の相関関係
The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is a pilot, prospective, observational study to estimate the degree to which baseline and early interval 18F-FDG PET/CT imaging within 3-4 weeks of ICI therapy initiation can accurately correlate with ctDNA level trends, predict clinical response, onset of immune-related adverse events, and survival outcomes in advanced stage melanoma patients.
Primary Objective
• To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks correlates with ctDNA level changes in advanced melanoma patients.
Secondary Objectives
- To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks predicts clinical efficacy at standard disease assessment time points in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT predicts development of clinical irAEs in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts progression-free survival (PFS) in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts overall survival (OS) in advanced melanoma patients.
研究の種類
研究の種類
入学 (実際)
入学
連絡先と場所
研究場所
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53792
- University of Wisconsin Hospitals and Clinics (UWHC)
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
24 participants with advanced stage III or stage IV melanoma with measurable disease who are deemed appropriate for treatment with ICI therapy.
説明
Inclusion Criteria:
- Willing to provide informed consent.
- Must have an advanced stage III or stage IV melanoma diagnosis for which treatment with ipilimumab, nivolumab, and/or pembrolizumab, either alone or in combination with other ICI therapy, is planned.
- Must be planning to participate in Signatera™ (ctDNA level) monitoring with standard of care laboratory testing routinely obtained for treatment with ICI therapy.
- Individuals at least 18 years of age.
- Women of childbearing potential must be willing to use effective contraception as discussed with their oncologist while participating in this study.
- Willing to comply with all study procedures and be available for the duration of the study.
Exclusion Criteria:
- Not able to receive treatment with ICI therapy
- Use of investigational drugs, biologics, or devices within 30 days prior to enrollment.
- Women who are pregnant, lactating, or planning on becoming pregnant during the study.
- Not suitable for study participation due to other reasons at the discretion of the investigators.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
免疫チェックポイント阻害剤を投与された進行性黒色腫患者
|
research scan 3-4 weeks after start of immunotherapy
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in ctDNA level from baseline to 3-4 week after the start of therapy
時間枠:baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
ctDNA level is monitored per standard of care in this population, data from chart review. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Change in 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
時間枠:baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy reported as SUV max. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Correlation between ctDNA level change and 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
時間枠:baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy with quantitative changes in ctDNA levels at baseline and at 3-4 weeks after starting ICI therapy. Pearson's or Rank's correlation coefficient will be used to measure the baseline measures for ctDNA level trends and PET/CT responses and for those measurements at 3-4 weeks. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Diagnostic Accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition as measured by Area under the Curve
時間枠:baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Receiver-operator curve analysis will be performed to determine the diagnostic accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition (area under the curve). |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate (ORR)
時間枠:up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. ORR is Partial Response (PR) plus Complete Response (CR). |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Disease Control Rate (DCR)
時間枠:up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. DCR is Stable Disease (SD) plus PR plus CR. |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Change in Standard Uptake Value (SUV) metrics with onset of Immune Related Adverse Events (irAE)
時間枠:up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate organ-level FDG uptake and changes from the baseline and early 18F-FDG PET/CT assessment with onset of first, second, and third symptomatic irAE per CTCAE v5.0 |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Progression Free Survival (PFS)
時間枠:up to 3 years after the first ICI dose (approximately 3 years on study)
|
PFS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and PFS
時間枠:up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early 18F-FDG PET/CT treatment response with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and PFS
時間枠:up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early ctDNA level trends with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Overall Survival (OS)
時間枠:up to 3 years after the first ICI dose (approximately 3 years on study)
|
OS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and OS
時間枠:up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early 18F-FDG PET/CT response assessment with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and OS
時間枠:up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early ctDNA level trends with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Vincent Ma, MD、University of Wisconsin, Madison
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 2023-1089
- A534260 (その他の識別子:UW Madison)
- UW23077 (その他の識別子:UWCCC)
- Protocol Version 2/12/2024 (その他の識別子:UW Madison)
- NCI-2023-11059 (レジストリ識別子:NCI Trial ID)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。